P2Y11 Antagonist B7508: Unraveling Its Role in Targeted Cell Signaling and Breast Cancer Invasion

Introduction

Cellular communication via G protein-coupled receptors (GPCRs) orchestrates a myriad of physiological and pathological processes, with purinergic signaling emerging as a central player in immunity, neurobiology, and cancer. Among the family of P2Y receptors, P2Y11 stands out for its unique dual coupling to G_s and G_q proteins, influencing both cyclic AMP and phospholipase C pathways. The P2Y11 antagonist (SKU: B7508), chemically known as sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate, provides a potent and selective tool for dissecting P2Y11-mediated GPCR signaling. While previous reviews have focused on workflow optimization and systems biology perspectives, this article bridges the mechanistic molecular action of P2Y11 antagonism with its emerging translational relevance in breast cancer invasion and immune modulation, offering a comprehensive resource for advanced researchers.

Molecular Profile and Properties of P2Y11 Antagonist (B7508)

Chemical Characteristics

B7508 is a beige solid with a molecular weight of 986.84 g/mol and the chemical formula C₃₇H₂₆N₄Na₄O₁₅S₄. Its highly water-soluble nature (maximum <19.74 mg/ml) ensures compatibility with aqueous assay systems. The compound, as a sodium salt, is recommended for storage at -20°C and is shipped on blue ice to maintain stability, crucial for preserving its antagonist activity. Given its complex aromatic and sulfonated structure, B7508 is optimized for rapid, reversible binding to the P2Y11 receptor and is intended strictly for research use—not for diagnostic or therapeutic applications.

Mechanism of Action: A Selective Cell Signaling Inhibitor Targeting P2Y11

The P2Y11 antagonist functions as a cell signaling inhibitor targeting the P2Y11 receptor by competitively blocking ATP and related agonists from activating this GPCR. P2Y11's dual coupling activates both adenylyl cyclase (increasing cAMP) and phospholipase C (PLC, generating IP₃/DAG and mobilizing intracellular Ca²⁺). By antagonizing this receptor, B7508 modulates GPCR signaling pathways pivotal to inflammatory responses, immune cell migration, and, as recent evidence suggests, cancer cell invasiveness.

GPCR Signaling Pathway Modulation: Beyond Conventional Inhibition

While the role of P2Y11 in immune cell function and cytokine release is well-documented, recent research has illuminated its involvement in cancer metastasis via the regulation of cytoskeletal dynamics. This advanced understanding stems from studies on breast cancer cell lines, where the inhibition of P2Y11 disrupts downstream Rho/ROCK and myosin light chain (MLC) phosphorylation, attenuating the invasive phenotype. Such findings position B7508 not only as a G protein-coupled receptor antagonist but also as a molecular probe to interrogate the intersection of purinergic signaling and cellular motility.

Scientific Evidence: Linking P2Y11 Antagonism to Breast Cancer Invasion

Reference Study Analysis

A seminal study by Liu et al. (Frontiers in Endocrinology, 2021) provides compelling evidence for the translational potential of P2Y11 antagonists. The research demonstrates that quinolinate phosphoribosyltransferase (QPRT), a key enzyme in NAD⁺ metabolism, is upregulated in aggressive breast cancer subtypes. QPRT overexpression enhances cell migration and invasion through MLC phosphorylation—a process partially reversed by P2Y11 antagonism with NF340 (B7508). This mechanistic link establishes a crucial axis: QPRT-driven invasiveness is, at least in part, orchestrated through P2Y receptor signaling, specifically via P2Y11. The study further differentiates the P2Y11 antagonist's action from inhibitors of Rho, ROCK, PLC, and MLCK, highlighting its upstream regulatory role in this pro-metastatic cascade.

Implications for Autoimmune Disease and Neuroinflammation Studies

The ability of B7508 to modulate P2Y11-dependent pathways extends its utility beyond oncology. Given the centrality of GPCR signaling in immune cell trafficking and cytokine release, P2Y11 antagonists are now being employed in autoimmune disease research and neuroinflammation studies. By attenuating excessive purinergic signaling, B7508 offers a novel approach to dissecting pathogenic mechanisms underlying chronic inflammation and degenerative disorders.

Advanced Applications: From Bench to Translational Research

Immunology Research and Inflammation Pathway Modulation

B7508 has emerged as a valuable tool in immunology research, specifically for investigating T cell and monocyte responses to extracellular nucleotides. By acting as a cell signaling inhibitor targeting the P2Y11 receptor, researchers can delineate the contribution of purinergic signaling to inflammation pathway modulation—critical for understanding cytokine storms, autoimmune flares, and tissue injury responses. Furthermore, the compound's selectivity allows for precise interrogation of the P2Y receptor signaling landscape, distinguishing P2Y11-mediated effects from those of other family members.

Unique Contribution: Integrative Mechanistic and Translational Perspective

While previous articles such as "P2Y11 Antagonist: Mechanisms and Applications in GPCR Sig..." have thoroughly explored P2Y11's role in GPCR signaling and inflammation, this article uniquely integrates the mechanistic findings from breast cancer invasion models and highlights the translational bridge to therapeutic target discovery. Unlike existing workflow-centric or systems biology articles, we emphasize the upstream regulatory role of P2Y11 in cancer metastasis and its convergence with NAD⁺ metabolic pathways, as elucidated in the Liu et al. study.

Comparative Analysis: P2Y11 Antagonist Versus Alternative Pathway Inhibitors

Alternative strategies for modulating invasiveness in cancer and immune cells include inhibitors of Rho (Y16), ROCK (Y27632), PLC (U73122), and MLCK (ML7). While these agents target downstream effectors within the GPCR signaling pathway, P2Y11 antagonists like B7508 act at the receptor level, preventing the initiation of multiple pro-inflammatory and pro-migratory cascades. This upstream inhibition not only confers greater specificity but also reduces off-target effects, making B7508 especially valuable for dissecting complex signaling networks. Moreover, as highlighted in the reference paper, only P2Y11 antagonism was able to reverse QPRT-induced MLC phosphorylation in parallel with other pathway inhibitors—emphasizing its central regulatory role.

Building on the applied workflow and troubleshooting guidance provided in "P2Y11 Antagonist in GPCR Signaling: Advanced Research App...", this article shifts focus to the strategic application of B7508 in pathway dissection, highlighting comparative advantages and study design considerations for translational research.

Experimental Considerations and Best Practices

Compound Handling and Assay Design

B7508’s water solubility facilitates its integration into in vitro and ex vivo models. However, due to its tendency for solution instability, it is recommended that freshly prepared solutions be used promptly to preserve activity. For sensitive assays, such as those probing rapid calcium fluxes or phosphorylation events, working at concentrations below the solubility threshold (<19.74 mg/ml) ensures accurate and reproducible results. Appropriate negative and positive controls, including alternative pathway inhibitors, should be incorporated to clarify the specificity of observed effects.

Storage and Shipping

The stability of B7508 is maintained by storage at -20°C and shipment on blue ice. These conditions prevent degradation and ensure consistency across experimental batches—a crucial factor for reproducibility in multi-center studies or longitudinal analyses.

Future Directions: P2Y11 Antagonist in Precision Medicine

The convergence of metabolic and signaling pathways in disease pathogenesis presents new opportunities for targeted intervention. As demonstrated by Liu et al., the interaction between QPRT-driven NAD⁺ metabolism and P2Y11-mediated signaling represents a promising axis for therapeutic exploration in breast cancer. Moving forward, the development of next-generation P2Y11 antagonists and the incorporation of B7508 into in vivo models and patient-derived organoids will be pivotal. Further, high-content screening and systems-level analyses may uncover additional roles for P2Y11 in neuroinflammatory and autoimmune contexts.

For readers interested in broader perspectives—such as systems biology applications, translational integration, and comparative market intelligence—see the discussion in "P2Y11 Antagonist B7508: A Systems Biology Perspective on ...". Our current analysis complements these works by providing a mechanistic and disease-model-focused lens, empowering researchers to bridge basic science and clinical translation.

Conclusion

The P2Y11 antagonist B7508 stands at the intersection of cutting-edge GPCR biology, cancer metastasis research, and immune modulation. Its ability to selectively inhibit the P2Y11 receptor and disrupt key signaling pathways provides researchers with a unique tool to unravel the complex web of cell signaling in health and disease. Integrating recent mechanistic insights with practical application guidance, this article underscores B7508’s value in advancing translational research—charting a path toward new therapeutic strategies for cancer, autoimmune, and neuroinflammatory disorders.